Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -8.14% is 74% below its 5-year average of -4.68%, around the middle of its 5-year range (-16.84%–9.36%).
As of the fiscal period ended Tuesday, June 30, 2026. 24.46% below its 12-month average of -6.54%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-06-30): -8.14%.
RETURN ON EQUITY (ROE)
-8.14%
RETURN ON EQUITY (ROE) AVG TTM
-6.54%
RETURN ON EQUITY (ROE) AVG 3Y
-5.60%
RETURN ON EQUITY (ROE) AVG 5Y
-4.68%
RETURN ON EQUITY (ROE) AVG 10Y
0.32%
RETURN ON EQUITY (ROE) AVG 15Y
3.27%
RETURN ON EQUITY (ROE) AVG 20Y
4.43%
CURRENT VS TTM AVG
-24.46%
CURRENT VS 3Y AVG
-45.33%
CURRENT VS 5Y AVG
-73.97%
CURRENT VS 10Y AVG
-2669.07%
CURRENT VS 15Y AVG
-348.71%
CURRENT VS 20Y AVG
-283.54%
SECTOR MEDIAN · HEALTHCARE
-41.38%
median of 714 covered companies
CURRENT VS SECTOR MEDIAN
+80.33%
vs the sector median at left
Azenta, Inc.
Market Cap
$1.83B
Return on Equity (ROE)
-8.14%
TTM Avg
-6.54%
3Y Avg
-5.60%
5Y Avg
-4.68%
Market Cap
$1.84B
Return on Equity (ROE)
-28.45%
TTM Avg
-88.46%
3Y Avg
-128.76%
5Y Avg
-100.86%
Market Cap
$1.84B
Return on Equity (ROE)
4.88%
TTM Avg
4.47%
3Y Avg
6.79%
5Y Avg
5.89%
Market Cap
$1.82B
Return on Equity (ROE)
15.62%
TTM Avg
13.87%
3Y Avg
11.38%
5Y Avg
11.40%
Market Cap
$1.81B
Return on Equity (ROE)
-32.46%
TTM Avg
-24.39%
3Y Avg
-19.07%
5Y Avg
-12.85%
Market Cap
$1.81B
Return on Equity (ROE)
-8.95%
TTM Avg
-23.57%
3Y Avg
-73.07%
5Y Avg
-68.36%
Market Cap
$1.80B
Return on Equity (ROE)
N/A
TTM Avg
36.48%
3Y Avg
36.48%
5Y Avg
36.48%
Market Cap
$1.87B
Return on Equity (ROE)
-15.90%
TTM Avg
-35.70%
3Y Avg
-33.44%
5Y Avg
-75.43%
Market Cap
$1.80B
Return on Equity (ROE)
N/A
TTM Avg
-157.29%
3Y Avg
-33.70%
5Y Avg
49.06%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Azenta, Inc. (AZTA) | $1.83B | -8.14% | -6.54% | -5.60% | -4.68% |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.84B | -28.45% | -88.46% | -128.76% | -100.86% |
| Astrana Health, Inc. (ASTH)vs › | $1.84B | 4.88% | 4.47% | 6.79% | 5.89% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.82B | 15.62% | 13.87% | 11.38% | 11.40% |
| Xencor, Inc. (XNCR)vs › | $1.81B | -32.46% | -24.39% | -19.07% | -12.85% |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.81B | -8.95% | -23.57% | -73.07% | -68.36% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.80B | N/A | 36.48% | 36.48% | 36.48% |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.87B | -15.90% | -35.70% | -33.44% | -75.43% |
| Novavax, Inc. (NVAX)vs › | $1.80B | N/A | -157.29% | -33.70% | 49.06% |
| Novocure Ltd (NVCR)vs › | $1.79B | -43.94% | -43.41% | -41.23% | -29.16% |
ROE
-8.1%
ROA
-6.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -8.14% |
| 2026-03-31 | -11.46% |
| 2025-12-31 | -3.37% |
| 2025-09-30 | -3.10% |
| 2025-06-30 | -6.63% |
| 2025-03-31 | -3.80% |
| 2024-12-31 | -9.37% |
| 2024-09-30 | -9.37% |
| 2024-06-30 | -7.83% |
| 2024-03-31 | -6.82% |
| 2023-12-31 | -0.81% |
| 2023-09-30 | -0.60% |
| 2023-06-30 | -1.50% |
| 2023-03-31 | -1.62% |
| 2022-12-31 | -16.84% |
| 2022-09-30 | -12.76% |
| 2022-06-30 | -11.23% |
| 2022-03-31 | -9.72% |
| 2021-12-31 | 9.36% |
| 2021-09-30 | 8.36% |
| 2021-06-30 | 9.02% |
| 2021-03-31 | 7.30% |
| 2020-12-31 | 6.22% |
| 2020-09-30 | 5.34% |
| 2020-06-30 | 3.40% |
| 2020-03-31 | 2.89% |
| 2019-12-31 | 2.40% |
| 2019-09-30 | 2.56% |
| 2019-06-30 | 4.80% |
| 2019-03-31 | 6.97% |
| 2018-12-31 | 15.68% |
| 2018-09-30 | 16.24% |
| 2018-06-30 | 17.36% |
| 2018-03-31 | 16.94% |
| 2017-12-31 | 10.42% |
| 2017-09-30 | 10.30% |
| 2017-06-30 | 9.46% |
| 2017-03-31 | 8.23% |
| 2016-12-31 | -9.22% |
| 2016-09-30 | -12.55% |
| 2016-06-30 | -13.53% |
| 2016-03-31 | -13.82% |
| 2015-12-31 | 1.98% |
| 2015-09-30 | 2.25% |
| 2015-06-30 | 1.25% |
| 2015-03-31 | 3.93% |
| 2014-12-31 | 3.99% |
| 2014-09-30 | 4.88% |
| 2014-06-30 | 5.65% |
| 2014-03-31 | 2.24% |
| 2013-12-31 | 1.66% |
| 2013-09-30 | -0.35% |
| 2013-06-30 | 17.33% |
| 2013-03-31 | 18.27% |
| 2012-12-31 | 19.56% |
| 2012-09-30 | 21.08% |
| 2012-06-30 | 6.21% |
| 2012-03-31 | 17.40% |
| 2011-12-31 | 20.98% |
| 2011-09-30 | 24.78% |
| 2011-06-30 | 27.35% |
| 2011-03-31 | 20.46% |
| 2010-12-31 | 20.63% |
| 2010-09-30 | 15.17% |
| 2010-06-30 | 5.68% |
| 2010-03-31 | -6.43% |
| 2009-12-31 | -61.23% |
| 2009-09-30 | -71.40% |
| 2009-06-30 | -129.21% |
| 2009-03-31 | -115.00% |
| 2008-12-31 | -52.76% |
| 2008-09-30 | -43.60% |
| 2008-06-30 | -2.84% |
| 2008-03-31 | 1.48% |
| 2007-12-31 | 15.37% |
| 2007-09-30 | 17.62% |
| 2007-06-30 | 17.49% |
| 2007-03-31 | 17.43% |
| 2006-12-31 | 7.24% |
| 2006-09-30 | 3.31% |
| 2006-06-30 | 0.34% |
| 2006-03-31 | -1.79% |
| 2005-12-31 | -2.72% |
| 2005-09-30 | -3.25% |
| 2005-06-30 | 1.77% |
| 2005-03-31 | 5.38% |
| 2004-12-31 | 8.08% |
| 2004-09-30 | 5.66% |
| 2004-06-30 | -13.13% |
| 2004-03-31 | -30.28% |
| 2003-12-31 | -43.94% |
| 2003-09-30 | -114.46% |
| 2003-06-30 | -392.67% |
